tiprankstipranks
Trending News
More News >
OncoZenge AB (SE:ONCOZ)
:ONCOZ

OncoZenge AB (ONCOZ) AI Stock Analysis

Compare
0 Followers

Top Page

SE

OncoZenge AB

(Frankfurt:ONCOZ)

Rating:41Neutral
Price Target:
OncoZenge AB faces substantial financial hurdles, with key weaknesses in profitability and cash flow, which are critical for the company's future viability. Technical analysis indicates bearish momentum, further exacerbating the company's challenges. Valuation metrics reflect its current unprofitability, offering little incentive for investors. Without significant strategic changes, the company's financial health remains precarious.

OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)

OncoZenge AB Business Overview & Revenue Model

Company DescriptionOncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel therapeutic solutions that improve patient outcomes. OncoZenge operates within the biotechnology and pharmaceutical sectors, concentrating on the development of proprietary drug formulations and delivery systems designed to enhance the efficacy and safety of cancer therapies.
How the Company Makes MoneyOncoZenge AB generates revenue primarily through the development and commercialization of its proprietary cancer treatments. The company may earn income from licensing agreements with other pharmaceutical companies, allowing them to market and distribute OncoZenge's products in various regions. Additionally, OncoZenge might engage in partnerships or collaborations with research institutions and industry peers to co-develop new therapies, potentially leading to shared revenues. The company may also seek funding through grants, research subsidies, or investment from private and public sources to support its research and development activities.

OncoZenge AB Financial Statement Overview

Summary
OncoZenge AB is facing significant financial challenges, particularly in terms of profitability and cash flow. The company's strong equity position and lack of debt provide some buffer, but persistent losses and declining revenues highlight the need for strategic adjustments to improve financial performance and ensure long-term viability.
Income Statement
30
Negative
OncoZenge AB has struggled with profitability, consistently reporting negative net income and EBIT margins, indicative of high operating expenses relative to revenue. Revenue growth was negative, as total revenue declined significantly from 2023 to 2024. The company has a high gross profit margin, but this is overshadowed by substantial losses.
Balance Sheet
55
Neutral
The company maintains a strong equity position, with no debt and a high equity ratio at 86.98% in 2024. However, the return on equity is negative due to consistent net losses. The financial stability is supported by substantial cash reserves, but the ongoing losses could pose a risk to long-term sustainability if not addressed.
Cash Flow
25
Negative
Operating cash flow remains negative, reflecting challenges in generating cash from operations. The free cash flow has deteriorated, indicating potential liquidity issues. The ratios of operating and free cash flow to net income are unfavorable, underscoring inefficiencies in cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.00K3.00K0.000.000.00
Gross Profit1.00K3.00K0.000.000.00
EBITDA-8.69M7.27M-43.57M-4.89M-801.00K
Net Income-8.69M-15.90M-46.65M-3.89M-636.00K
Balance Sheet
Total Assets11.43M20.34M36.89M85.23M38.30M
Cash, Cash Equivalents and Short-Term Investments3.86M12.63M29.14M51.22M10.00M
Total Debt0.000.000.000.000.00
Total Liabilities1.48M1.70M2.92M4.90M9.01M
Stockholders Equity9.95M18.64M33.97M80.32M29.28M
Cash Flow
Free Cash Flow-8.76M-17.08M-22.08M-10.12M-1.00K
Operating Cash Flow-8.76M-17.08M-22.08M-4.77M-1.00K
Investing Cash Flow0.00570.00K0.00-5.36M0.00
Financing Cash Flow0.000.000.0051.34M10.00M

OncoZenge AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.00
Price Trends
50DMA
5.32
Positive
100DMA
5.51
Positive
200DMA
5.89
Positive
Market Momentum
MACD
0.38
Negative
RSI
61.73
Neutral
STOCH
79.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Positive. The current price of 7 is above the 20-day moving average (MA) of 6.16, above the 50-day MA of 5.32, and above the 200-day MA of 5.89, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 79.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ONCOZ.

OncoZenge AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
€48.91M
78.14%-94.12%-25.83%
50
Neutral
kr5.39B12.66-80.61%5.12%37.36%27.71%
42
Neutral
kr44.56M-222.24%58.36%
41
Neutral
kr79.18M-46.84%45.38%
39
Underperform
kr53.18M-147.64%30.02%-3985.71%
38
Underperform
kr104.81M-105.78%58.72%70.69%
34
Underperform
kr105.91M-56.71%35.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ONCOZ
OncoZenge AB
6.59
2.68
68.54%
SE:BIOSGN
Biosergen AB
0.46
0.09
22.99%
SE:LARK
CombiGene AB
2.42
-0.43
-15.12%
SE:MODTX
Modus Therapeutics Holding AB
1.21
-0.07
-5.49%
SE:SPAGO
Spago Nanomedical AB
0.31
0.02
7.29%
SE:SPRINT
Sprint Bioscience AB
0.49
-0.83
-62.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025